Overview

Effects of Ramelteon (8mg) Alone and in Combination With Multi-Component Behavioral Therapy on Sleep and Circadian Phase in Patients With Chronic Insomnia

Status:
Unknown status

Trial end date:
2010-09-01

Target enrollment:

Participant gender:

Summary

The specific aims of the proposed study are to compare the sleep, daytime functioning, and circadian phase effects of ROZEREMTM (ramelteon/TAK-375) a selective MT1/MT2 melatonin receptor agonist in humans alone and in combination with multi-component behavior therapy (MCBT) in patients with chronic insomnia.

Phase:

Phase 4

Details

Lead Sponsor:

University of Arizona

Collaborator:

University of Colorado, Denver